Skip to main content
OpenTrials

Clinical trial condition

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Explore clinical trials studying Metastatic Castration-resistant Prostate Cancer (mCRPC). Study availability and eligibility vary by location and protocol.

34 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC) trial results

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • The University of Arizona Cancer Center - North Campus ( Site 0073) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0044) Los Angeles, California, United States
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) Orange, California, United States
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center (0120) Orange, California, United States
View all 329 locations
View Trial Details
Recruiting

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

NCT07493512

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • United States Oncology Regulatory Affairs Corporate Office Denver, Colorado, United States
  • US Oncology Research Investigational Products Center Denver, Colorado, United States
  • Thomas Jefferson University Philadelphia, Pennsylvania, United States
View Trial Details
Recruiting

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

NCT07594106

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • City of Hope Phoenix Goodyear, Arizona, United States
  • City of Hope Duarte, California, United States
  • City of Hope Chicago, City of Hope Cancer Center Chicago Zion, Illinois, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +48 more
Locations
  • Exelixis Clinical Site #67 Phoenix, Arizona, United States
  • Exelixis Clinical Site #1 Tucson, Arizona, United States
  • Exelixis Clinical Site #123 Palo Alto, California, United States
  • Exelixis Clinical Site #59 Santa Barbara, California, United States
View all 122 locations
View Trial Details
Recruiting

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

NCT07570979

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Mary Crowley Cancer Research Dallas, Texas, United States
  • Novartis Investigative Site Melbourne, Victoria, Australia
  • Novartis Investigative Site Hirakata, Osaka, Japan
View Trial Details
Recruiting

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

NCT03972657

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • University of Arizona Tucson, Arizona, United States
  • John Wayne Cancer Institute (JWCI) Santa Monica, California, United States
View all 24 locations
View Trial Details
Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674

Conditions
Adenoma, Adnexal Diseases, Breast Diseases, +75 more
Locations
  • City of Hope Duarte, California, United States
  • University of Southern California Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • University of Colorado School of Medicine Aurora, Colorado, United States
View all 17 locations
View Trial Details
Recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

NCT06134232

Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Locations
  • Arizona Urology Specialists Tuscon, Arizona, United States
  • City of Hope - National Medical Center Duarte, California, United States
  • Urology Associates of Central California Medical Group Fresno, California, United States
  • Unio Health Partners - Genesis Research, LLC San Diego, California, United States
View all 31 locations
View Trial Details

Related conditions